Genfit and labcorp sign exclusive agreement to commercialize a novel diagnostic test for liver disease

Genfit and labcorp sign exclusive agreement to commercialize a novel diagnostic test for liver disease.test is expected to be available from labcorp by early 2021.innovative multi-biomarker blood test based on genfit's nis4™ technology is specifically designed to identify patients with at-risk non-alcoholic steatohepatitis (nash).labcorp to commercialize test for clinical care use in u.s. and canada to help identify approximately 10 million individuals at risk of progressing to late stage complications due to nash among tens of millions of people with metabolic risk factors and suspected disease.
LH Ratings Summary
LH Quant Ranking